PIK3CA Could Guide Use of COX-2 Inhibitors in Treatment for Colon Cancer
Patients with stage III resected colon cancer with PIK3CA gain-of-function mutations treated with celecoxib had improved DFS, OS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.